Dyne Therapeutics Inc (NASDAQ:DYN) has a beta value of 0.95 and has seen 2.07 million shares traded in the last trading session. The company, currently valued at $2.13B, closed the last trade at $26.28 per share which meant it lost -$1.71 on the day or -6.11% during that session. The DYN stock price is -15.18% off its 52-week high price of $30.27 and 75.65% above the 52-week low of $6.40. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.18 million shares traded. The 3-month trading volume is 2.16 million shares.
Dyne Therapeutics Inc (NASDAQ:DYN) trade information
Sporting -6.11% in the red in last session, the stock has traded in the green over the last five days, when the DYN stock price touched $26.28 or saw a rise of 9.63%. Year-to-date, Dyne Therapeutics Inc shares have moved 97.59%, while the 5-day performance has seen it change 2.86%. Over the past 30 days, the shares of Dyne Therapeutics Inc (NASDAQ:DYN) have changed 11.36%. Short interest in the company has seen 6.61 million shares shorted with days to cover at 5.27.
Dyne Therapeutics Inc (DYN) estimates and forecasts
Figures show that Dyne Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 183.80% over the past 6 months, with this year growth rate of 18.23%, compared to 11.30% for the industry. Other than that, the company has, however, increased its growth outlook for the 2024 fiscal year revenue. Growth estimates for the current quarter are -2.60% and 25.90% for the next quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -106.26% over the past 5 years.
DYN Dividends
Dyne Therapeutics Inc is expected to release its next earnings report on March 05 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Dyne Therapeutics Inc (NASDAQ:DYN)’s Major holders
Insiders own 0.95% of the company shares, while shares held by institutions stand at 93.48% with a share float percentage of 94.37%. Investors are also buoyed by the number of investors in a company, with Dyne Therapeutics Inc having a total of 186 institutions that hold shares in the company. The top two institutional holders are Atlas Venture Life Science Advisors, LLC with over 9.89 million shares worth more than $111.21 million. As of Jun 29, 2023, Atlas Venture Life Science Advisors, LLC held 16.20% of shares outstanding.
The other major institutional holder is MPM Asset Management, LLC, with the holding of over 4.95 million shares as of Jun 29, 2023. The firm’s total holdings are worth over $55.7 million and represent 8.11% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. As of Jun 29, 2023, the former fund manager holds about 2.38% shares in the company for having 1.45 million shares of worth $16.35 million while later fund manager owns 0.99 million shares of worth $11.26 million as of Aug 30, 2023, which makes it owner of about 1.62% of company’s outstanding stock.
